These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9749452)

  • 1. Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies.
    O'Neill RT
    Stat Med; 1998 Aug 15-30; 17(15-16):1851-8; discussion 1859-62. PubMed ID: 9749452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Good pharmacovigilance practices: technology enabled.
    Nelson RC; Palsulich B; Gogolak V
    Drug Saf; 2002; 25(6):407-14. PubMed ID: 12071777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some observations on pharmacoepidemiology in Europe.
    van Boxtel CJ; Wang G
    Neth J Med; 1997 Dec; 51(6):205-12. PubMed ID: 9499691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods for observational post-licensure medical product safety surveillance.
    Nelson JC; Cook AJ; Yu O; Zhao S; Jackson LA; Psaty BM
    Stat Methods Med Res; 2015 Apr; 24(2):177-93. PubMed ID: 22138688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.
    Shakir SA; Layton D
    Drug Saf; 2002; 25(6):467-71. PubMed ID: 12071785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China.
    Yang Y; Zhou X; Gao S; Lin H; Xie Y; Feng Y; Huang K; Zhan S
    Drug Saf; 2018 Jan; 41(1):125-137. PubMed ID: 28815480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses.
    Gentili M; Pozzi M; Peeters G; Radice S; Carnovale C
    Curr Clin Pharmacol; 2018; 13(1):28-39. PubMed ID: 29412117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Erice Manifesto: for global reform of the safety of medicines in patient care.
    Drug Saf; 2007; 30(3):187-90. PubMed ID: 17343426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From pharmacovigilance to pharmacoperformance.
    Peachey J
    Drug Saf; 2002; 25(6):399-405. PubMed ID: 12071776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
    Hauben M; Reich L; Gerrits CM
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of risk measures in pharmacoepidemiology with tips for statisticians in the pharmaceutical industry.
    Quartey G; Wang J; Kim J
    Pharm Stat; 2011; 10(6):548-53. PubMed ID: 22127819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Translation and introduction of Guide to Methodological Standards in Pharmacoepidemiology].
    Tian F; Liao X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2949-57. PubMed ID: 24471310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.
    Lopalco PL; DeStefano F
    Vaccine; 2015 Mar; 33(13):1541-8. PubMed ID: 25444788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
    Maier WC; Christensen RA; Anderson P
    Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting.
    Crisafulli S; Khan Z; Karatas Y; Tuccori M; Trifirò G
    Expert Opin Drug Saf; 2023; 22(5):373-380. PubMed ID: 37243676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on method on post-marketing traditonal Chinese medicine safety assessment].
    Kou Q; Zhao S; Feng G; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2771-5. PubMed ID: 22292361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicine use in pregnancy and public cord blood bank databases.
    Spartano S; Bianchi M; Murgi E; Giannadrea S; Landini A; Barbagallo O; Screnci M; Girelli G; Zini G; Teofili L
    Pharmacoepidemiol Drug Saf; 2014 Oct; 23(10):1107-9. PubMed ID: 25316303
    [No Abstract]   [Full Text] [Related]  

  • 20. Ethical considerations in post-market-approval monitoring and regulation of vaccines.
    Thompson A; Komparic A; Smith MJ
    Vaccine; 2014 Dec; 32(52):7171-4. PubMed ID: 25454882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.